Both in Biotechnology
Surrozen vs Allogene Therapeutics
Over the past year SRZN returned +130.6% and ALLO returned −5.1%; their daily moves had a correlation of 0.13.
SRZN +130.6% ALLO −5.1%Growth of $1, one year, split-adjusted
| Metric | SRZN | ALLO |
|---|---|---|
| Price | $30.12 | $1.12 |
| Market cap | $354.0M | $386.9M |
| Today | +3.79% | +2.75% |
| 1 month | +3.4% | −25.3% |
| 6 months | −7.7% | −48.4% |
| Year to date | +33.3% | −18.2% |
| 1 year | +115.1% | −9.7% |
| Revenue growth (YoY) | +408.6% | — |
| Gross margin | 100.0% | 100.0% |
| Net margin | 640.8% | −919.8% |
| P/E (TTM) | — | — |
| Price / sales | 30.8× | 83.4× |
| Net cash | $102.0M | $332.6M |
| Dividend yield | — | — |
| Volatility (60d) | 170.8% | 54.4% |
| Short % of float | 37.0% | 19.4% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).